Clinical Trial News and Research

RSS

Chemo-immunotherapy combination shows promise against pancreatic cancer

A combination of chemotherapy with an immunotherapy meant to unleash the anticancer capacity of the immune system was effective against one of the hardest targets in cancer care, pancreatic cancer, in a national, randomized clinical trial led by researchers at the Perelman School of Medicine at the University of Pennsylvania, and sponsored by the Parker Institute for Cancer Immunotherapy.

6 Jun 2022

Electronic symptom monitoring improved quality-of-life outcomes among patients with metastatic cancer

People with advanced cancer who communicated their symptoms weekly using an electronic survey had about a one-third better physical function and over a 15% better control of their symptoms compared to those who were evaluated less frequently via in-person clinical visits, according to findings from a multi-state study conducted at 52 community cancer clinics.

6 Jun 2022

Drug combination yields highest response and longest survival rates for patients with pancreatic NETs

Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors (NETs), but researchers at the Yale Cancer Center and Yale New Haven Health's Smilow Cancer Hospital found that patients treated with a combination of capecitabine and temozolomide had longer progression-free survival rates than those treated with temozolomide alone.

6 Jun 2022

Study confirms the benefits of 'bridge therapy' for some children with high-risk neuroblastoma

Approximately half of children with neuroblastoma - a childhood cancer that develops from immature nerve cells - have a form that indicates a high likelihood of recurrence.

6 Jun 2022

New trial examines the effectiveness of combination immunotherapy for platinum-resistant ovarian cancer

A new clinical trial studying the effectiveness of a combination of immunotherapy treatments could be more effective for patients with ovarian cancer who are resistant to traditional interventions.

6 Jun 2022

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial's prespecified level for statistical significance.

4 Jun 2022

Study: Nearly 43% of patients with KRAS-mutated lung cancer respond to experimental drug adagrasib

Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.

3 Jun 2022

Peer-led, family-centered preventive intervention promotes mental health among Bhutanese immigrants in the U.S.

After years of working with Bhutanese community members in Western Massachusetts, a team led by a University of Massachusetts Amherst researcher has developed a peer-led, family-centered preventive intervention to reduce stress, anxiety and depressive symptoms and promote mental health among immigrants in the U.S.

3 Jun 2022

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology Annual Meeting.

3 Jun 2022

Millions of COVID-19 patients may have undiagnosed acute kidney injury, finds study

A University of Queensland-led study has found millions of COVID-19 patients may have undiagnosed acute kidney injury (AKI).

2 Jun 2022

Smokers hide cigarette packs with graphic warning labels in public, study finds

Smokers in the United States who received cigarette packs with graphic warning labels hid their packs 38% more often. However, smokers stopped hiding their cigarettes when they returned to regular packs without the graphic labels, reports a multi-institutional group of public health experts led by University of California San Diego.

2 Jun 2022

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.

2 Jun 2022

Genetically predicted height linked to risk for several common health conditions

A large genetic study by the U.S. Department of Veteran Affairs' Million Veteran Program (MVP)) has found that a person's height may affect their risk for several common health conditions in adulthood.

2 Jun 2022

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept - drugs widely used to treat certain autoimmune diseases - did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.

2 Jun 2022

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

The National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.

2 Jun 2022

Aerobic exercise amplifies the effects of immunotherapy to reduce pancreatic tumor growth

Aerobic exercise reprograms the immune system to reduce pancreatic tumor growth and amplify the effects of immunotherapy, a new study finds.

2 Jun 2022

Scientists develop new technology to solve common surgical problem of nerve damage

A research collaboration including scientists from Oregon State University has developed a new technology to help surgeons know where a patient's nerves are, lessening the chance of nerve damage.

1 Jun 2022

Combination bNAb therapy may offer a future alternative to daily ART for people living with HIV

Individuals with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs), according to a small study published today in the journal Nature.

1 Jun 2022

Gene therapy for degenerative retinal disease has no safety concerns but fails to improve vision loss

A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries visual signals from the light-sensing retina to the brain.

1 Jun 2022

Antibiotics ravage motivation and endurance in athletes

New research demonstrates that by killing essential gut bacteria, antibiotics ravage athletes' motivation and endurance.

1 Jun 2022

Clinical Trial News and Research

Chemo-immunotherapy combination shows promise against pancreatic cancer

Electronic symptom monitoring improved quality-of-life outcomes among patients with metastatic cancer

Drug combination yields highest response and longest survival rates for patients with pancreatic NETs

Study confirms the benefits of 'bridge therapy' for some children with high-risk neuroblastoma

New trial examines the effectiveness of combination immunotherapy for platinum-resistant ovarian cancer

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

Study: Nearly 43% of patients with KRAS-mutated lung cancer respond to experimental drug adagrasib

Peer-led, family-centered preventive intervention promotes mental health among Bhutanese immigrants in the U.S.

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Millions of COVID-19 patients may have undiagnosed acute kidney injury, finds study

Smokers hide cigarette packs with graphic warning labels in public, study finds

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Genetically predicted height linked to risk for several common health conditions

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

Aerobic exercise amplifies the effects of immunotherapy to reduce pancreatic tumor growth

Scientists develop new technology to solve common surgical problem of nerve damage

Combination bNAb therapy may offer a future alternative to daily ART for people living with HIV

Gene therapy for degenerative retinal disease has no safety concerns but fails to improve vision loss

Antibiotics ravage motivation and endurance in athletes

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer